 HOLON, Israel, June 30, 2021 PRNewswire -- Compugen Ltd. NASDAQ: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the first patient has been dosed in the combination expansion cohort of its ongoing Phase 1 clinical trial evaluating COM701, Compugens first-in-class anti-PVRIG antibody, in combination with Opdivo nivolumab. 